Back

RBC reaffirms outperform rating on Oxford BioMedica despite partner trial pauses

Verifying
  • RBC Capital Markets reaffirmed its outperform rating on Oxford BioMedica.
  • Novartis and BMS paused clinical trials involving Oxford BioMedica partners.
  • RBC estimated annual clinical r... at £10 million to £16 million.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.